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Edited by Jesus AvilaAbstract Protein phosphatase (PP)-2A, which regulates the
phosphorylation of tau, is regulated by two endogenous inhibitor
proteins, IPP2A1 and I
PP2A
2 , in mammalian tissues. Here, we report
the cloning of IPP2A1 and I
PP2A
2 from human brain, and show that
in PC12 cells and in IPP2A1 GFP or IPP2A2 GFP transfected
NIH3T3 and human neural progenitor cells, IPP2A1 is localized
mostly in the cell cytoplasm and IPP2A2 mostly in the nucleus.
The recombinant IPP-2A1 and I
PP-2A
2 inhibit PP-2A activity to-
wards hyperphosphorylated tau in vitro; the dephosphorylation
of the hyperphosphorylated tau at speciﬁc sites is selectively
inhibited. Overexpression of IPP2A1 as well as I
PP2A
2 results in
tau hyperphosphorylation and degeneration of PC 12 cells.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The presence of numerous neurons with neuroﬁbrillary tan-
gles of paired helical ﬁlaments (PHF) in the neocortex, espe-
cially the hippocampus, is a neuropathological hallmark of
Alzheimer disease (AD). The microtubule associated protein
tau is abnormally hyperphosphorylated in AD brain and is
the major protein subunit of PHF [1–5]. The abnormally
hyperphosphorylated tau is also present in the aﬀected neurons
as amorphous aggregates and as a cytosolic protein [2,6–10].
However, the mechanisms of hyperphosphorylation of tau
are not yet established. Generally, the level of phosphorylation
of a protein is regulated by the equilibrium between the activ-
ities of its protein kinases and phosphatases.
The activities of phosphoseryl/phosphothreonyl protein
phosphatases (PP)-2A and PP-1 are compromised in AD brainAbbreviations: AP-1, activator protein-1; AD, Alzheimer disease; GFP,
green ﬂuorescent protein; GST, glutathione-S-transferase; LANP, le-
ucine-rich acidic nuclear protein; MAP, microtubule associated pro-
tein; PHF, paired helical ﬁlaments; PCR, polymerase chain reaction;
PHAP, putative histocompatibility leukocyte antigen class II-associ-
ated protein; TAF-1b, template activating factor-1b
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and not PP-2B activity by cyclosporin-A produces in metabol-
ically active brain slices from adult rats the abnormal hyper-
phosphorylation of tau that inhibits its binding to
microtubules and the promotion of their assembly in vitro
[13]. Furthermore, the activities of several protein kinases
which phosphorylate tau are regulated by PP-2A [14–17].
Thus, it is strongly suspected that PP-2A, which also regulates
the activity of PP-1 through dephosphorylation of PP-1 inhib-
itors, I-1/DARPP-32, might be involved in the abnormal
hyperphosphorylation of tau and that the abnormally phos-
phorylated tau can indeed be responsible for the AD neuroﬁ-
brillary degeneration.
The PP-2A activity is regulated by two endogenous inhibitor
proteins, IPP2A1 and I
PP2A
2 , in mammalian tissue (for review see
[18]). These two proteins do not inhibit the activities of PP-1,
PP-2B and PP-2C, the other three major serine/threonine pro-
tein phosphatases or aﬀect the activities of a number of protein
kinases studied in vitro [19]. Both IPP2A1 and I
PP2A
2 have been
cloned from human kidney [20,21]. Both proteins inhibit holo-
enzyme forms of PP-2A, probably by binding directly to the
catalytic subunit. The puriﬁed preparations of IPP2A1 and
IPP2A2 inhibit PP-2A in vitro in a manner non-competitive with
the substrate [19]. In intact cells, overexpression of IPP-2A2 re-
sults in increased expression, DNA-binding and Ser-63 phos-
phorylation of c-Jun, and in higher transcriptional activity of
activator protein-1 (AP-1) [22]. These eﬀects are reversed by
overexpression of hemagglutinin-tagged PP-2Ac, consistent
with IPP-2A2 acting as a PP-2A inhibitor in vivo. I
PP2A
1 and
IPP2A2 associate with and modify the substrate speciﬁcity of
PP-1 in the presence of physiological concentration of Mn2+,
suggesting a novel role for IPP2A1 and I
PP2A
2 in the coordination
of PP-1 and PP-2A activities within cells [23].
IPP-2A1 has been found to be the same protein as the putative
histocompatibility leukocyte antigen class II-associated protein
(PHAP)-I [21]. Proteins homologous to IPP-2A1 have been iso-
lated and described as mapmodulin [24], pp32 [25], and leu-
cine-rich acidic nuclear protein (LANP) [26]. Proteins
homologous to IPP-2A2 have also been isolated and described
as human SETa [21,27], PHAP-II, and template activating fac-
tor-1b (TAF-1b) [28]. SET, in its complete form, is a nuclear
protein and contains a highly acidic C-terminal region that is
involved in chromatin remodeling. SET itself is also a potent
and speciﬁc inhibitor of PP-2A [21], and exerts its inhibitory
activity via its N-terminal part [29]. TAF-1b protein which
lacks the C-terminal region and also inhibits PP-2A activityblished by Elsevier B.V. All rights reserved.
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is a nuclear protein [30]. However, these inhibitors have not yet
been isolated and characterized from brain.
The present study describes the cloning and the characteriza-
tion of IPP2A1 and I
PP2A
2 from human brain, the immunocytolog-
ical localization of these inhibitors in cultured cells, and the
inhibition of PP-2A catalyzed dephosphorylation of abnor-
mally hyperphosphorylated tau at speciﬁc sites by these two
inhibitors.2. Materials and methods
2.1. Cloning and generation of brain IPP2A1 and I
PP2A
2
Polymerase chain reaction (PCR) was used to generate probes spe-
ciﬁc for IPP2A1 and I
PP2A
2 . The 31-mer oligonucleotide 5
0-CGA AGA
TCT ATG GAG ATG GGC AGA CGG ATT C-3 0 as the 5 0 primer
and the 33-mer oligonucleotide 5 0-GCA GTC GAC GTC ATC ATC
TTC TCC CTC ATC TTC as the 3 0 primer to the sequence of human
kidney IPP-2A1 cDNA were designed. The 33-mer oligonucleotide 5
0-
CGT AGA TCT ATG TCG GCG CCG GCG GCC AAA GTC
and the 33-mer oligonucleotide 5 0-GCT GTC GAC GTC ATC TTC
TCC TTC ATC CTC CTC were designed as the 5 0 primer and the
3 0 primer, respectively, to the sequence of human kidney IPP-2A2 cDNA.
The reaction mixture for PCR contained cDNA derived from human
brain Marathon-Ready cDNA library (Clontech, Palo Alto, CA) as
a template. PCR ampliﬁcation was performed with 30 cycles, using a
cycle of denaturation for 30 s at 92 C, annealing for 40 s at 68 C,
and an extension for 2 min at 68 C. The PCR product was digested
with BglII and SalI (Promega, Madison, WI), cloned into a pEGFP-
N3 Vector (Clontech), and sequenced. To remove the green ﬂuorescent
protein (GFP) region of these two plasmids, they were retransformed
with INV100 competent cells (Invitrogen, Carlsbad, CA), digested with
SalI and XbaI (Promega), and then treated with Klenow fragment
(New England Biolabs, Beverly, MA) and religated.2.2. Cell culture and transfections
NIH 3T3 cells (obtained from ATCC, Rockville, MD) were grown
in 25 cm2 ﬂasks at 37 C, containing 5% CO2 in DMEM supplemented
with 10% bovine calf serum. Cells were plated on coverslips and trans-
fected with expression plasmids of IPP2A1 GFP or IPP2A2 GFP using
Lipofectamine Plus Reagent according to the manufacturers instruc-
tions (Life Technologies, Inc., Rockville, MD). At 24 h post-transfec-
tion, these cells were processed for indirect immunoﬂuorescence.
Human neural progenitor cells were grown on dishes coated with
0.01% poly-D-lysine (Sigma, St. Louis, MO) in Neurobasal medium.
Cells were transfected with expression plasmids as above using Lipo-
fectamine Plus Reagent according to the manufacturers instructions.
At 72 h post-transfection, the human progenitor cells were processed
for indirect immunoﬂuorescence.
PC12 cells or tau 441 stably transfected PC12 cells were grown in 25
cm2 ﬂasks at 37 C, maintained at 5% CO2 in RPMI medium 1640
(Gibco) supplemented with 10% bovine calf serum, 5% horse serum,
and 1% penicillin. Cells were plated in 8 well Lab-Tek II Chamber
Slides (Nalge Nunc International, Naperville, IL) and then transfected
with expression plasmid using Lipofectamine 2000 according to the
manufacturers instructions (Invitrogen). At 24, 48 and 72 h post-
transfection, cells were processed for indirect immunoﬂuorescence
and LDH assay.
2.3. Immunocytochemical staining
Human neural progenitor cells and NIH 3T3 cells transiently trans-
fected with IPP2A1 GFP or IPP2A2 GFP as well as non-transfected
PC12 cells were ﬁxed with 4% paraformaldehyde in 0.1 M phosphate
buﬀered saline (PBS) and immunostained with 1 lg/ml rabbit aﬃnity
puriﬁed antibody R-42089 to a synthetic peptide corresponding to
amino acid residues 10–23 of human IPP-2A1 [31], or with 2 lg/ml rab-
bit aﬃnity puriﬁed antibody R-42187 to a synthetic peptide corre-
sponding to amino acid residues 18–29 of human SET=IPP-2A2 [31],
followed by incubation with anti-rabbit Alexa 594 conjugate,
1:2000 dilution. The antibody R-42089 recognizes IPP2A1 but notIPP2A2 . Similarly, antibody R-42187 recognizes I
PP2A
2 and not I
PP2A
1
[31]. Representative images from several cells were generated using
a Nikon PCM 2000 Confocal Imaging System.
In the case of PC12 cells transfected with IPP2A1 or I
PP2A
2 , at 72 h post-
transfection, cells were ﬁxed with 4% paraformaldehyde in 0.1 M PBS
and were treated with 0.1% Triton-X in TBS for 5 min and were
blocked with 5% defatted milk in TBS for 30 min and with primary
antibodies in the same buﬀer overnight at 4 C. The primary antibodies
used were mAb PHF-1 (to phosphorylated Ser 396/404, 1:100) [32,33],
mAb Tau-1 (to unphosphorylated Ser 195, 198, 199 or 202; 1:50 000)
[1,34,35], mAb M4 (to phosphorylated Thr 231/Ser 235; 1:2000) [36],
mAb 43D (to total tau; 1:2000), mAb DM1A (to alpha-tubulin;
1:2000) (Sigma), pAb 92e (to total tau; 1:5000) [37], pAb 134d (to total
tau; 1:5000) [38], rabbit aﬃnity puriﬁed antibody R-42089 to a syn-
thetic peptide corresponding to amino acid residues 10–23 of kidney
IPP2A1 , and rabbit aﬃnity puriﬁed antibody R-42187 to a synthetic pep-
tide corresponding to amino acid residues 18–29 of kidney IPP2A2 . Fluo-
rescent secondary antibodies used were cy3 anti-rabbit and anti-mouse
(Fab1)
2 antibodies (1:1000; Molecular Probes, Eugene, OR). Represen-
tative images from several cells were generated using a Nikon PCM
2000 Confocal Imaging System.
2.4. Western blots
NIH3T3 cells grown in 175-cm2 ﬂasks were washed once and
scraped in ice-cold PBS. Cells were then lysed in lysis buﬀer (50 mM
HEPES, pH 7.5, 1% Triton X-100, 50 mM NaCl, 5 mM EGTA, 50
mM sodium ﬂuoride, 20 mM sodium pyrophosphate, 1 mM sodium
vanadate, 2 mM PMSF, and 8 mM diisopropylﬂuorophosphate).
The cell lysates were subjected to SDS–PAGE and transferred to
PVDF membranes. The levels of GFP, IPP2A1 and I
PP2A
2 were visualized
using anti-mouse GFP antibody (Quantum Biotechnology, Inc., Mon-
treal, Canada), 1:1000 dilution, rabbit antibodies R-42089 (1 lg/ml) to
IPP2A1 and R-42187 (1 lg/ml) to I
PP2A
2 [31]. As secondary antibodies,
alkaline phosphatase-labeled goat anti-mouse, 1:2000 dilution, or
anti-rabbit IgG, 1:2000, were used and membranes were developed
by 5-bromo-4-chloro-3-indolylphosphate p-toluidine salt and nitroblue
tetrazolium chloride. Western blots of GST IPP2A1 and GST IPP2A2
were developed as above using either monoclonal antibody B5E7 to
GST [39] or antibodies to IPP2A1 or I
PP2A
2 .
2.5. Northern blots
Multiple Tissue Northern (MTN) blots (Clontech), which are
hybridization-ready Northern blots prepared using Clontechs high-
quality premium RNA, were used. The probe used was the 32P-labeled
PCR products, which was made with Random printed DNA labeling
kit (Roche, Indianapolis, IN).2.6. Generation of recombinant GST  IPP-2A1 , GST  IPP2A2 ; IPP2A1 and
IPP2A2
The PCR products for IPP2A1 and I
PP2A
2 were separately digested with
BglII and SalI, cloned into a glutathione-S-transferase (GST) gene fu-
sion vector, pGEX-4T-2 Vector (Amersham Pharmacia Biotech, Piscat-
away, NJ), and sequenced. Puriﬁcation and detection of GST fusion
protein produced in E. coliwere carried out using the GSTGene Fusion
system (Amersham Pharmacia Biotech). A single colony of E.coli cells
containing recombinant PGEX 4T-2 with IPP2A1 or I
PP2A
2 plasmid was
picked and used to inoculate 3 ml of 2X YTA medium at 37 C with
shaking overnight. Then, 1 ml of this liquid culture was employed to
inoculate 1L 2X YTA medium at 37 C with shaking until the AS600
nm reached 0.6–0.8. At this stage, IPTGwas added to a ﬁnal concentra-
tion of 0.2 mM and the cells were grown for an additional 3 h. The cul-
tured cells were centrifuged at 7700 · g for 20 min at 4 C, and the
pellets were drained and saved for the puriﬁcation of the inhibitors.
The pellets were suspended in lysis buﬀer (50 mM TBS, pH 7.6, 1
mM PMSF, 0.1 mM benzamidine and protease inhibitor cocktail [Sig-
ma]) and sonicated on ice (pulsed 60%, 9 mm sonication tip) for 1.5 min
for 5 times (interval time between sonications was 5 min) and centri-
fuged at 12 000 · g for 10 min, followed by 100 000 · g for 20 min.
These pellets were discarded and the supernatant was passed through
Glutathione Sepharose 4B column. The column was washed with
TBS and then eluted with 10 mM glutathione, 50 mM Tris–HCl, pH
8.0. To purify the recombinant IPP2A1 and I
PP2A
2 , recombinant
GST IPP-2A1 or GST IPP2A2 protein was treated with thrombin
(Amersham Pharmacia Biotech) for 24 h ðGST IPP-2A1 Þ or for 3 h
Table 1
Tau antibodies employed
Antibody Type Epitope
134da Poly Total tau
P Thr-231 Poly pThr-231
M4 Mono pThr-231/pSer-235
P Ser-262 Poly pSer-262
12E8 Mono pSer-262/356
P Ser-396 Poly pSer-396
PHF-1 Mono pSer-396/404
aPhospho-independent and total tau.
P: phospho-dependent and phosphorylated epitope.
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through and wash with TBS and 0.5 M NaCl in TBS were collected,
combined, passed through HiTrap Benzamidine FF column (Amer-
sham Pharmacia Biotech) to remove the thrombin from the inhibitors
in the ﬂow-through. The inhibitors were concentrated by ultraﬁltration
(Millipore, Bedford, MA) in 50 mM imidazole, pH 7.2, 0.2 mMEGTA,
0.02%BME and 0.1 mg/ml BSA and stored at75 C till used. The pur-
ity of the recombinant proteins was conﬁrmed by SDS–PAGE and
Western blots. The recombinant proteins were heated in sample buﬀer
(in 20 mM Tris, pH 6.8, 1% SDS, 1% BME, and 10% glycerol/bromo-
phenol blue), and then subjected to SDS–PAGE (10% polyacrylamide)
and Coomassie blue staining and to Western blots developed with
mouse anti-GST antibody, dilution of 1:1000, IPP2A1 antibody (2.5 lg/
ml) or IPP2A2 antibody (5 lg/ml). The recombinant proteins were used
for the inhibition of PP-2A activity in the phosphatase assay and for
radioimmuno-dot-blot assay.2.7. Preparation of [32P] hyperphosphorylated tau and phosphatase
assay
Phosphatase assays were carried out using 32P-labeled hyperphosph-
orylated tau as a substrate. Hyperphosphorylation of recombinant hu-
man brain tau352 was performed by using 100 000 · g brain extract
from a 20 day-old rat as the source of protein kinases as described pre-
viously [5,40]. The reaction was carried out at 32 C using 0.25 mg/ml
tau protein and 1 ll of brain extract (16 000 · g extract of 33% homog-
enate) per 20 ll of phosphorylation buﬀer (60 mM HEPES, pH 7.4, 8
mM MgCl2, 5 mM EGTA, 2 mM ATP, 2 mM DTT, 20 nM calyculin
A, and 1 mM 4-[2-aminoethylamino]-benzenesulfonyl ﬂuoride
[AEBSF, a serine protease inhibitor]). After 2 h and 8 h of incubation,
NaF (17 mM) and ATP (cold plus 32P, 2 mM), respectively, were
added [5]. At the end of reaction, 5 mM BME and 100 mM NaCl were
added and the reaction mixture was heated in a boiling water bath for
5 min. After heat treatment, the mixture was centrifuged at 16 000 · g
for 15 min and tau which is heat stable was collected as supernatant.
Tau from the supernatant was then precipitated and washed with
15% TCA/2 mM ATP three times and then with 10% TCA three times.
The pellet was solubilized at 4 C in 0.1 mM NaOH and then neutral-
ized with 0.1 mM HCl to pH 7.5.
The inhibition of PP-2A activity by IPP2A1 and I
PP2A
2 was determined
in 50 mM Tris, pH 7.0, 0.1 mM EDTA, 7.5 mM caﬀeine, and 10 mM
BME using PP-2A1 puriﬁed from bovine brain as a holoenzyme [41],
32P-labeled hyperphosphorylated tau as a substrate, and recombinant
inhibitors as such or as GST fusion proteins. Reactions were initiated
with 32P-labeled hyperphosphorylated tau, and to stop the reaction
after 20 min at 30 C samples were chilled on ice for 10 min. 32P-la-
beled tau was then separated from free 32P using paper chromatogra-
phy [42]. The radioactivity was measured by Cerenkov Method in a
scintillation counter. These samples were also used for radioimmuno-
dot-blot assays, after storage at 75 C for more than 10 half-life
periods of 32P till the radioactive signal was negligible.2.8. LDH assay for cell viability
The eﬀect of the overexpression of IPP2A1 or I
PP2A
2 on the degeneration
of PC12 cells was determined by assaying the LDH release using the
Cyto Tox-ONEe Assay kit (Promega). PC12 cells were transfected
with IPP2A1 ; I
PP2A
2 , N3 (mock) or pcDNA (mock) in 96 well microtiter
plates. AT 24, 48 and 72 h post-transfection, the LDH release was as-
sayed, and degeneration calculated as: % cell death = (experimental 
culture medium background) · 100/(maximum LDH release · culture
medium background).2.9. Radioimmunodot blotting assay
Levels of phosphorylated and unphosphorylated taus were deter-
mined by radioimmunodot blot assays [8,43]. Samples were diluted
(2 ng/ll) in dilution buﬀer (50 mM Tris, pH 7.6, 0.1% SDS, 200 mM
NaCl, 1 mM PMSF, 50 mM NaF, 1 mM Na3VO4, 2 lg/ml aprotinin,
2 lg/ml leupeptin, and 1 lg/ml pepstatin) and were applied onto nitro-
cellulose membranes at 3 ll/cm2. Membranes were blocked for 1 h with
5% defatted milk, then blots were overlaid with phospho-independent
or phospho-dependent tau antibodies (see Table 1) at room tempera-
ture overnight with shaking. After washing three times with TBS, the
blots were overlaid with 125I-labeled anti mouse or rabbit IgG for 2
h at room temperature. The blots were washed with TBS containing0.1% Tween 20 overnight, then washed three times for 30 min, fol-
lowed by drying the blots and counting the radioactivity in a Fuji
BAS 1500 phosphorimager.3. Results
Cloning of IPP2A1 and I
PP2A
2 fromhuman brain andmRNAexpres-
sion in various tissues and brain regions. To determine the struc-
tures of brain IPP2A1 and I
PP2A
2 , we cloned these cDNAsof proteins
from human brain using human Marathon-Ready cDNA li-
brary and primers generated for the human kidney IPP2A1 and
IPP2A2 cDNAs. The nucleotide sequences of the brain cDNAs of
IPP2A1 and I
PP2A
2 were 7.56 kb and 8.40 kb, respectively (Fig. 1).
The mRNAs of IPP2A1 and I
PP2A
2 were investigated by North-
ern blot analysis. The IPP-2A1 probe hybridized in Northern
blots to three transcripts of 4.2, 3.7 and 2.2 kb in all tissues
(heart, brain, placenta, lung, liver, skeletal muscle, kidney
and pancreas) examined (Fig. 2(a)). Strong signals in kidney
and skeletal muscle, moderate signals in brain, placenta and
pancreas and weak signals in lung were observed (Fig. 2(a-i)
to (a-iv)). In brain, the 3.7 kb transcript was the most promi-
nent and the 2.2 kb signal was the weakest of all the three tran-
scripts. IPP-2A1 probe hybridized in all brain regions (amygdala,
caudate nucleus, corpus callosum, hippocampus, brain [whole]
and thalamus) examined (Fig. 2(b)). The strongest signal was
detected in amygdala (Fig. 2(b-i) to (b-iv)).
The size of SET gene mRNA, which is homologous to IPP-2A2 ,
was previously reported to be 2.7 and 2.0 kb on Northern blots
in mouse tissues with human SET cDNA probe [30]. In the
present study, Northern blots analysis showed that IPP-2A2
probe hybridized prominently to two transcripts of 2.7 kb
and 1.9 kb and weakly to a transcript of 4.0 kb in all tissues
examined (Fig. 2(c)). The strong signals were detected in pla-
centa and brain (Fig. 2(c-i) to (c-iv)). IPP-2A2 probe hybridized
in all brain regions examined (Fig. 2(d)). Strong signals were
detected in amygdala, hippocampus and thalamus (Fig. 2(d-
i) to (d-iv)). These results suggested that IPP2A1 and I
PP2A
2
mRNAs were localized in all human tissues, including the
areas of the brain, i.e., amygdala and hippocampus that are
most aﬀected by neuroﬁbrillary degeneration in AD.
Isolation of recombinant human brain IPP2A1 and I
PP2A
2 and Inhi-
bition of PP-2A activity towards hyperphosphorylated tau by
these inhibitors. To determine the activities of IPP2A1 and I
PP2A
2 ,
we generated these inhibitors as recombinant GST fusion pro-
teins and then cleaved them from GST with thrombin. SDS–
PAGE and Western blots of the isolated IPP2A1 and I
PP2A
2 had
molecular size of 30 and 40 kDa, respectively (Fig. 3).
The GST IPP-2A1 and GST IPP-2A2 had apparent molecular
size of 60 and 70 kDa, respectively.
Fig. 1. Nucleotide sequence of human brain IPP-2A1 and I
PP-2A
2 cDNAs. Underlines indicate the oligonucleotides used to generate the cDNAs and
location of the introduced BglII and SalI sites. Genbank accession numbers of human brain IPP2A1 and I
PP2A
2 are AY349171 and AY349172,
respectively.
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PP-2A, we carried out PP-2A assays with 32P-labeled hyper-
phosphorylated tau352 as a substrate. Previously, it was re-
ported that the puriﬁed preparations of IPP-2A1 and I
PP-2A
2
inhibited PP-2A-catalyzed dephosphorylation of 32P-labeled
myelin basic protein, 32P-labeled histone H1, 32P-labeled pyru-
vate dehydrogenase complex, and 32P-labeled phosphorylase
[19]. Because of interest in the regulation of PP-2A activity to-
wards hyperphosphorylated tau, we carried out PP-2A assay
with 32P-labeled hyperphosphorylated tau352 as a substrate.
The recombinant IPP-2A1 , I
PP-2A
2 and GST IPP-2A1 inhibited
but neither GST nor GST IPP2A2 inhibited PP-2A activity in
vitro with hyperphosphorylated tau as a substrate (Fig. 3).
Half-maximal inhibition of PP2A with IPP-2A1 and
GST IPP-2A1 occurred at about 600 nM, and with I2PP-2A at
about 400 nM. The apparent Ki for IPP-2A1 and GST IPP-2A1
was about 480 nM, and for IPP-2A2 was about 300 nM. The
Kis for IPP-2A1 ; I
PP-2A
2 with
32P-labeled hyperphosphorylated
tau352 as a substrate were 10–20 times higher than those with
other 32P-labeled substrates reported previously [19].
Diﬀerential inhibition of PP-2A activity towards AD speciﬁc
phosphorylated sites of tau by IPP2A1 and I
PP2A
2 . Tau is abnor-mally hyperphosphorylated at speciﬁc sites in AD and diﬀerent
sites have diﬀerent eﬀects on the biological activity of tau
[44,45]. We therefore investigated the inhibition of PP-2A
activity towards diﬀerent abnormally phosphorylated sites of
tau by IPP2A1 and I
PP2A
2 . For these studies, we ﬁrst established
the time kinetics of the dephosphorylation of the hyperphosph-
orylated tau by PP-2A at each speciﬁc site using phospho-
dependent antibodies and a polyclonal antibody to total tau
(see Table 1). The dephosphorylation reaction was found to
be linear up to 15 min incubation at 32 C and during this
incubation less than 15% of the substrate was dephosphoryl-
ated (data not shown). Employing 10 min incubation at 32
C, we determined both the dephosphorylation of tau by PP-
2A at each speciﬁc site (Table 2) and the inhibition of this
activity by IPP-2A1 ; I
PP-2A
2 or GST IPP-2A1 employing their IC50
concentrations towards hyperphosphorylated tau in the above
studies. PP-2A was found to dephosphorylate tau with diﬀer-
ent eﬃciency at diﬀerent sites (Table 2). The dephosphoryla-
tion of tau at 12E8 (Ser-262/356) and at Thr-231 was found
to be most and least eﬃcient by PP-2A. IPP-2A1 inhibited the
dephosphorylation of tau most eﬃciently at 12E8 (Ser-262/
356) and PHF-1 (Ser-396/404) sites, while IPP-2A2 had the corre-
Fig. 2. Northern blots showing the e xpression of IPP2A1 and I
PP2A
2 mRNAs in diﬀerent human tissues and brain regions. The cDNA probes used were
PCR products. IPP2A1 probe (a,b) or I
PP2A
2 probe (c,d) was hybridized to RNAs of various human tissues (a,c) or brain regions (b,d). Northern blots in
a, b, c and d were scanned and values obtained were normalized to brain as 100% (i–iv). The size (kb) of the transcripts detected are indicated on the
left and the standards on the right of the panels.
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(Table 3). Like IPP2A1 , the GST IPP2A1 fusion protein inhibited
the PP-2A activity towards the hyperphosphorylated tau but
the relative inhibitory activities of the two proteins were vari-
able at each phosphorylation site studied, especially at 12E8
site.
Immunocytological localization of IPP2A1 and I
PP2A
2 in cultured
cells. To determine the cytological localization of IPP2A1 and
IPP2A2 , NIH3T3 cells and human neural progenitor cells trans-
fected with IPP2A1 GFP or IPP2A2 GFP, and untransfected
PC12 cells were immunostained with antibodies to IPP2A1 or
IPP2A2 . Endogenous I
PP2A
1 was localized both in the cytoplasm
and nuclei, whereas endogenous IPP2A2 was seen mostly in the
nuclei of PC12 cells (Fig. 4(a)). Overexpression of
IPP-2A1 GFP was found both in the cytoplasm and the nucleus
but mostly in the former in NIH3T3 cells and in human neural
progenitor cells. Overexpression of IPP-2A2 GFP was observed
mostly in the nucleus both in NIH3T3 cells and human pro-
genitor cells. The overexpression of the GFP fusion proteins
was conﬁrmed biochemically in the cell lysates. Western blots
developed with antibodies to GFP revealed a 60 kDa
(IPP-2A1 GFP) band and a 70 kDa ðIPP-2A2 GFPÞ band inIPP-2A1 transfected and I
PP-2A
2 transfected NIH3T3 cells, respec-
tively (Fig. 4(b)).
Regulation of phosphorylation of tau and induction of cell
death by IPP2A1 and I
PP2A
2 . To study whether I
PP2A
1 and/or I
PP2A
2
regulate the phosphorylation of tau and cause cell death,
PC12 cells stably transfected with human brain tau441 or the
untransfected cells were transiently transfected with IPP2A1 or
IPP2A2 and its eﬀect on abnormal phosphorylation of tau at var-
ious sites in the cells was studied immunocytochemically.
Overexpression of IPP2A1 resulted in a marked increase in the
phosphorylation of tau at 12E8 and PHF-1 sites and a moder-
ate increase at M4 and Tau-1 sites (Fig. 5(a)). Mock transfec-
tion, i.e., vector alone of PC12 cells, did not reveal any
signiﬁcant changes in the phosphorylation of tau at any of
the above sites studied (data not shown). Immunocytochemical
staining with two diﬀerent phospho-independent polyclonal
antibodies revealed that the tau441 stably transfected PC12
cells employed for the studies had a similar expression of total
tau (data not shown). Overexpression of IPP2A2 resulted in an in-
crease in the phosphorylation of tau at 12E8, PHF-1, M4 and
Tau-1 sites (Fig. 5(b)); the increase was most noticeable at the
12E8 site. Mock transfected cells revealed no detectable change
Fig. 3. Eﬀect of recombinant human IPP-2A1 ; I
PP-2A
2 , GST IPP-2A1 , GST IPP-2A2 and GST on PP-2A. (a–e) The activity of PP-2A was measured as
described in Section 2 with 32P-labeled hyperphosphorylated tau352 as substrate in the presence of the indicated concentrations of puriﬁed
recombinant IPP-2A1 (a), and I
PP-2A
2 (b), GST-I
PP-2A
1 (c), GST-I2
PP-2A(d) and GST (e). (f) SDS–PAGE of recombinant GST IPP2A1 (lane 1, arrow),
GST IPP2A2 (lane 4, arrow), puriﬁed IPP2A1 (lane 2), IPP2A2 (lane 5) and Western blots of puriﬁed IPP2A1 (lane 3) and IPP2A2 (lane 6) developed with
corresponding antibodies.
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studied (data not shown). These ﬁndings suggested that both
IPP2A1 and I
PP2A
2 regulated the phosphorylation of tau at some
of the same sites known to be abnormally hyperphosphory-
lated in AD brain.
The abnormally hyperphosphorylated tau, which sequesters
normal tau, MAP1 and MAP2 and depolymerizes microtu-
bules [8–10], is suspected to lead to neurodegeneration in
AD and other tauopathies. We, therefore, investigated the ef-
fect of the overexpression of IPP2A1 and I
PP2A
2 on the viability of
the PC12 cells by the Cyto Tox-ONE assay. We found that in
a post-transfection time-dependent manner, both IPP2A1 and
IPP2A2 as such and as well as GFP-fusion proteins increased
the cell death by twofold during 72 h when compared withTable 2
Dephosphorylation of hyperphosphorylated tau at various sites by PP-
2A
Phosphorylated (%)a
Control 100
Thr-231 68.5 ± 6.1
M4 59.2 ± 8.3
Ser-262 41.3 ± 6.1
12E8 19.3 ± 3.6
Ser-396 42.1 ± 3.9
PHF-1 38.1 ± 4.8
aPhosphorylation before treatment with PP-2A as 100%.the corresponding mock transfected cells (Fig. 5(c)). These
ﬁndings suggested that inhibition of PP-2A activity by IPP2A1
or IPP2A2 alone is suﬃcient both to produce the abnormal hyper-
phosphorylation of tau as well as result in an increase in cell
death.4. Discussion
The activity of PP-2A, a major phosphoseryl/phosphoth-
reonyl protein phosphatase, is believed to be regulated by
IPP2A1 and I
PP2A
2 . However, neither the structures nor the activ-
ities of these inhibitors from brain had been reported previ-Table 3
Inhibition of PP-2A catalyzed dephosphorylation of tau at various
sites by IPP2A1 ; I
PP2A
2 or GST IPP2A1
Dephosphorylation (%)a
IPP2A1 I
PP2A
2 GST IPP2A1
Thr 231 73.6 ± 12.6 58.7 ± 11.4 96.2 ± 10.4
M4 51.6 ± 7.8 24.6 ± 6.2 41.3 ± 5.0
Ser 262 38.2 ± 11.0 36.6 ± 6.1 39.8 ± 10.2
12E8 26.8 ± 5.1 37.1 ± 3.4 58.9 ± 10.1
Ser 396 48.6 ± 6.2 52.0 ± 3.8 68.1 ± 6.8
PHF-1 31.8 ± 4.6 43.0 ± 6.2 39.0 ± 4.8
aDephosphorylation of tau by PP-2A in the absence of inhibitors as
100%.
Fig. 4. Immunocytochemical staining of untransfected PC12 cells, and NIH 3T3 cells and human neural progenitor cells transiently transfected with
IPP-2A1 GFP or IPP-2A2 GFP. (a) PC12 cells and at 24 h post-transfection, NIH3T3 cells and at 72 h post-transfection, progenitor cells were
processed for indirect immunoﬂuoresence. Scale bar: PC12 cells, 5 mm bar = 17.5 lm; NIH3T3 and neural progenitor cells, 5 mm bar = 6 lm. (b)
Western blots of NIH 3T3 cells transiently transfected with mock plasmid I-GFP (lane 3) or IPP-2A1 GFP (lane 2 4) or IPP-2A2 GFP(lane 1). The
levels of GFP, IPP-2A1 and I
PP-2A
2 were visualized using monoclonal antibody to GFP (lanes 2 and 3), polyclonal antibodies, R-42089 to I
PP-2A
1 (lane 4)
and R-42187 to IPP-2A2 (lane 1). I
PP-2A
1 GFP or IPP-2A2 GFP fusion proteins were detected in cells transfected with IPP-2A1 and IPP-2A2 , respectively.
Arrow shows GFP fusion IPP-2A1 or I
PP-2A
2 and arrowhead shows GFP.
Fig. 5. Immunocytochemical staining and cell survival of tau441 stably transfected PC12 cells transiently transfected with I
PP2A
1 or I
PP2A
2 . (a,b) At 72 h
post-transfection, cells were processed for double immunoﬂuorescence using rabbit polyclonal antibody to IPP2A1 or to I
PP2A
2 and mouse monoclonal
phosphodependent antibodies to tau as primary antibodies, followed by Oregon Green-labeled goat anti-rabbit (green; left panels), and cy3-labeled
anti-mouse (Fab1)2 (red; middle panels) as secondary antibodies (1:1000; Jackson Immuno Research). Mock transfected cells not shown in this ﬁgure
did not show any signiﬁcant changes in the immunochemical staining with any of the above antibodies. (c) PC12 cells were transfected with
IPP2A1 ; I
PP2A
2 , N3 (mock) or pcDNA (mock) plasmids. At 24 (red bar), 48 (green bar) and 72 (black bar) hours post-transfection, the viability of cells
was measured with the Cyto Tox-ONE Assay Kit (Promega). % cell death = (experimental  culture medium background)/(maximum LDH
release  culture medium background). Diﬀerences between IPP2A1 or IPP2A2 and mock transfected cells (pcDNA or N3), P < 0.05.
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of IPP2A1 and I
PP2A
2 in human brain and demonstrates in a site
speciﬁc manner the diﬀerential inhibition of PP-2A activity
towards Alzheimer-like hyperphosphorylated tau by these
two inhibitors. The data presented in this study also show
that both IPP2A1 and I
PP2A
2 regulate the phosphorylation of
tau and that overexpression of either one of these inhibitors
is suﬃcient to cause call death. All these ﬁndings taken to-
gether raise an intriguing possibility that the abnormal hyper-
phosphorylation of tau produced by inhibition of PP-2A
activity might be suﬃcient to produce neurodegeneration of
the Alzheimer type.
The nucleotide sequences of cDNAs of IPP2A1 and I
PP2A
2
cloned from human brain were found to be identical to those
reported previously for PHAP-I and human kidney IPP2A1
[21,28] and SET/IPP2A2 [21,27]. Northern blot analysis revealed
the presence of three transcripts of 4.2, 3.7 and 2.2 kb for
IPP-2A1 in human brain and other tissues studied. In the case
of IPP-2A2 , the Northern blots showed two prominent transcripts
of 2.7 and 1.9 kb and a third weak signal of 4.0 kb in human
brain and other tissues examined. Employing the human brain
cRNA probes of IPP2A1 and I
PP2A
2 from the present study, we
found 3.7 and 2.1 kb IPP2A1 and 2.9 and 2.0 kb I
PP2A
2 transcripts
in rat brain [31]. A previous study reported that IPP-2A2 homol-
ogous gene, Set a, encoded two transcripts of 2.0 and 2.7 kb in
adult mouse tissue [27]. It appears that in addition to the two
transcripts corresponding to the rodent tissues, the human tis-
sues contain novel larger transcripts of 4.2 kb IPP2A1 and 4.0 kb
IPP2A2 . Whether more than one transcript observed in Northern
blots code for a single protein and are due to diﬀerent lengths
of poly A tails or might represent alternatively spliced mRNAs
coding for proteins of diﬀerent sizes remains to be investigated
both in the case of IPP2A1 and I
PP2A
2 .
PP-2A activity is compromised in AD brain [11,12] and has
been speculated to be a cause of the hyperphosphorylation of
tau and neuroﬁbrillary degeneration. Amygdala and hippo-
campus are most aﬀected by neuroﬁbrillary changes in AD
brain. In the present study, the hybridization of IPP2A1 and
IPP2A2 probes in Northern blots of the various areas of the hu-
man brain was especially strong in amygdala and hippocam-
pus among various brain regions. This ﬁnding raises an
intriguing possibility of an involvement of these PP-2A inhib-
itors in Alzheimer neuroﬁbrillary degeneration. Consistent
with this scenario, in situ hybridization and immunohisto-
chemical studies have shown a wide distribution and a co-
localization of these inhibitors with PP-2A in mammalian
brain, especially in pyramidal cell layers of CA1-3 regions
and in the amygdaloid nucleus [31].
In non-transfected PC12 cells, endogenous IPP2A1 was local-
ized to cytoplasm and nucleus, whereas the endogenous IPP2A2
was observed mostly in the nucleus. A similar subcellular local-
ization of these inhibitors was observed by us in rat brain [31].
Both NIH3T3 and human neural progenitor cells could be suc-
cessfully transfected with IPP2A1 GFP and IPP2A2 GFP fusion
proteins. The overexpression of IPP2A1 GFP was observed
mostly in the cytoplasm, whereas that of IPP2A2 GFP was seen
mainly in the nucleus in both NIH3T3 and human neural pro-
genitor cells. These immunocytological localizations of IPP2A1
and IPP2A2 are in agreement with the previous reports [28,30].
Studies on template activating factor-1 which is the same as
IPP2A2 have shown that on cleavage the amino-terminal half
of the protein, which like the whole protein, also inhibits PP-2A activity, is both in the nuclear and cytoplasmic locations
[30]. Thus, not only IPP2A1 but also I
PP2A
2 can modulate the
PP-2A activity of the neuronal cytoplasmic pool where tau is
localized.
Previously, it was reported that both IPP2A1 and I
PP2A
2 puri-
ﬁed from bovine kidney inhibited the PP-2A-catalyzed
dephosphorylation of [32P]MBP, [32P]histone H1, [32P]pyru-
vate dehydrogenase complex and [32P]phosphorylase A [19].
In the present study, recombinant IPP2A1 ; I
PP2A
2 , and
GST IPP2A1 but not GST IPP2A2 inhibited the PP-2A activity
in vitro towards [32P] hyperphosphorylated human brain
tau352. These ﬁndings showed for the ﬁrst time that the PP-
2A inhibitors can aﬀect phosphorylation of tau, which is
known to be regulated by PP-2A. The loss of PP-2A inhibitor
activity in GST IPP2A2 fusion protein was probably due to
the unavailability of the inhibitor domain due to some con-
formational change induced in this protein. The Kis of the re-
combinant human brain IPP2A1 and I
PP2A
2 towards [
32P]
hyperphosphorylated tau were 480 and 300 nM, respectively.
These Ki values are about 10–20 fold higher than those re-
ported previously towards other [32P] substrates by inhibitors
puriﬁed from bovine kidney. These diﬀerences might be both
due to diﬀerences in the substrates and the sources of the
inhibitors.
Tau in AD brain is abnormally hyperphosphorylated at
multiple sites (see [44]). However, the phosphorylation of only
some of these sites has been shown to aﬀect the biological
activity of tau; the phosphorylation of tau at Thr-231, Ser-
262 and Ser-396 inhibits its binding to microtubules and their
assembly. The present study revealed that IPP2A1 and I
PP2A
2
inhibited the PP-2A catalyzed dephosphorylation of tau diﬀer-
entially and with site-speciﬁc preference at these functionally
important sites. While IPP2A1 was more eﬀective than I
PP2A
2 in
inhibiting the dephosphorylation of the PHF-1 site, the reverse
appeared to be the case at the M4 site. In all the cases, the
phospho-dependent monoclonal antibodies to tau distin-
guished better than the corresponding polyclonal antibodies
the diﬀerences between the inhibition of the dephosphorylation
by IPP2A1 and I
PP2A
2 .
The overexpression of IPP2A1 or I
PP2A
2 in PC12 cells revealed
that these inhibitors regulated the phosphorylation of tau at
several of the same sites, which are known to be abnormally
hyperphosphorylated in AD and other tauopathies, and
caused cell death. Like in vitro studies above in PC12 cells,
the phosphorylation of tau at the PHF-1 site was more mark-
edly increased in the IPP2A1 -transfected cells than in the I
PP2A
2 -
transfected cells, suggesting a diﬀerential eﬀect of the two
inhibitors on the dephosphorylation of tau by PP-2A. A
marked hyperphosphorylation of tau at the 12E8 site in both
IPP2A1 - and I
PP2A
2 -transfected PC12 cells is probably both due
to an inhibition of PP-2A activity as well as an increase in
the activity of CaMKinase II, the activity of which is regulated
by PP-2A [15]. CaMKinase II has been previously shown by us
to be a major 12E8 site tau kinase in the brain [46]. Similarly,
the increase in the phosphorylation of tau at the PHF-1, M4
and Tau-1 sites could be both due to inhibition of dephospho-
rylation by PP-2A as well as increase in the activities of one or
more tau kinases, the activities of which are regulated by PP-
2A [17,47].
In conclusion, IPP2A1 and I
PP2A
2 , the regulators of PP-2A
activity, are present in mammalian brain. In human brain,
the mRNAs of these two PP-2A inhibitors are especially
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the brain most aﬀected by neuroﬁbrillary pathology. IPP2A1 is
localized in both cytoplasm and the nucleus, whereas IPP2A2
is mostly seen in the nucleus. The recombinant human brain
IPP2A1 and I
PP2A
2 are biologically active and can inhibit the PP-
2A catalyzed dephosphorylation of the AD type abnormally
hyperphosphorylated tau in vitro. IPP2A1 and I
PP2A
2 inhibit the
dephosphorylation of tau in a site speciﬁc preference and dif-
ferentially at some of the major abnormally phosphorylated
sites seen in AD. Both IPP2A1 and I
PP2A
2 regulate the phosphor-
ylation of tau at several of the sites abnormally hyperphosph-
orylated in AD and cause cell death. All these ﬁndings taken
together suggest that the downregulation of IPP2A1 and/or I
PP2A
2
might inhibit abnormal hyperphosphorylation of tau and
consequent neuroﬁbrillary degeneration in AD and other tau-
opathies. We have previously shown that the restoration of
the okadaic acid-inhibited PP-2A activity to the normal levels
by memantine in rat hippocampal slices in culture inhibits the
abnormal hyperphosphorylation of tau and neurodegenera-
tion [47].
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